Utilization of hepatitis C virus–infected organ donors in cardiothoracic transplantation

Publication Date: May 1, 2020
Last Updated: March 14, 2022

Consensus statements

Consensus #1: The donor HCV profile should be characterized by the presence or absence of HCV viremia as detected by NAT and the presence or absence of anti-HCV antibodies as determined by serologic testing. In the case of HCV Ab−/NAT− donors that are considered Public Health Service IRDs, risk factors for HCV acquisition should be taken into account to help guide post-transplant surveillance.
6731

Overview

Title

Utilization of hepatitis C virus-infected organ donors in cardiothoracic transplantation

Authoring Organization